Drug Interactions between Banzel and Jadenu Sprinkle
This report displays the potential drug interactions for the following 2 drugs:
- Banzel (rufinamide)
- Jadenu Sprinkle (deferasirox)
Interactions between your drugs
No interactions were found between Banzel and Jadenu Sprinkle. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Banzel
A total of 502 drugs are known to interact with Banzel.
- Banzel is in the drug class dibenzazepine anticonvulsants.
- Banzel is used to treat Lennox-Gastaut Syndrome.
Jadenu Sprinkle
A total of 599 drugs are known to interact with Jadenu Sprinkle.
- Jadenu sprinkle is used to treat Iron Overload.
Drug and food/lifestyle interactions
deferasirox food/lifestyle
Applies to: Jadenu Sprinkle (deferasirox)
ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.
MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.
References (1)
- (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals
rufinamide food/lifestyle
Applies to: Banzel (rufinamide)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of rufinamide. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of rufinamide. In healthy volunteers, administration of a single 400 mg dose of rufinamide with food resulted in an approximately 56% increase in mean peak plasma concentration (Cmax) and a 34% increase in systemic exposure (AUC) compared to administration during a fasting state.
MANAGEMENT: To ensure maximal oral absorption, it is preferable to administer rufinamide with food. Patients receiving rufinamide should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how rufinamide affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (1)
- (2008) "Product Information. Banzel (rufinamide)." Eisai Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.